U.S. Stem Cell
U.S. Stem Cell is a company specializing in regenerative medicine and cell-based therapeutics, offering products and training for both human and veterinary applications.
Services
U.S. Stem Cell offers a broad range of services in both human and veterinary medicine. The company operates a cell therapy clinic and provides extensive in-clinic regenerative medicine solutions for physicians. Accredited training programs in regenerative medicine are also available for physicians worldwide. For veterinarians, U.S. Stem Cell offers a variety of regenerative medicine solutions through its veterinary division, Vetbiologics.
Products
U.S. Stem Cell has developed several cell-based therapeutic products. MyoCell® is a muscle stem cell therapy aimed at improving cardiac function after severe heart damage. AdipoCell™ is utilized in a Phase I/II trial for congestive heart failure patients and involves stem cells derived from the patient's fat. Additionally, the company offers a clinical protocol and kit under the AdipoCell™ brand to isolate a patient's own stem cells. These products have been used successfully in multiple clinical trials.
History
Founded in the late 1990s, U.S. Stem Cell has treated over 10,000 patients since 1999. The company has invested more than $125 million in research and development, focusing on the discovery, development, and commercialization of cell-based therapeutics. Over the years, U.S. Stem Cell has developed more than 30 protocols for various diseases and has opened several standalone and partnered stem cell clinics, both in the United States and worldwide. The company has completed more clinical treatments than any other stem cell company globally in the past 20 years.
Veterinary Stem Cell Products
U.S. Stem Cell's veterinary division, Vetbiologics, provides advanced regenerative medicine solutions tailored for veterinarians. This division focuses on animal health, aiming to cater to pet care, pain management, wellness, and geriatric care needs. Vetbiologics is actively looking to expand into the consumer-driven pet-care industry, leveraging its expertise in stem cell therapies.
Clinical Trials and Research
U.S. Stem Cell has a robust clinical trial program that has seen successful completion of Phase I, Phase I/II, and Phase II trials for MyoCell, with Phase II/III trials currently underway. MyoCell SDF-1 has shown a 54% improvement in heart function in preclinical studies and received FDA approval for human clinical trials. AdipoCell™ therapy, in collaboration with the Regenerative Medicine Institute in Tijuana, Mexico, is also in clinical trials aimed at addressing congestive heart failure and chronic ischemic cardiomyopathy.